Related Experiment Video
Updated: Jan 13, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
CTLA4-related primary immune dysregulatory disorders
Safa Baris1,2,3
1Division of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University.
Insights
Lifespan-limiting CTLA4-related immune disorders, including LRBA deficiency and CTLA-4 insufficiency, are better managed with abatacept and sirolimus. Early diagnosis and multidisciplinary care improve outcomes, with HSCT for high-risk cases.
Area of Science:
- Immunology
- Genetics
- Clinical Medicine
Background:
- CTLA4-related immune disorders are primary immune dysregulation syndromes.
- These disorders involve susceptibility to infections, autoimmunity, hyperinflammation, and malignancies.
- LRBA deficiency and CTLA-4 insufficiency are key examples requiring updated clinical guidance.
Purpose of the Study:
- To review current knowledge on LRBA deficiency and CTLA-4 insufficiency.
- To guide clinicians in diagnosing and managing these CTLA4-related immune disorders.
- To highlight emerging molecular mechanisms and therapeutic strategies.
Main Methods:
- Review of recent studies on LRBA/DEF6-mediated CTLA-4 recycling.
- Analysis of novel molecular interactions (NBEAL2, Arf1-Rab4) and BEACH-domain protein function.
- Clinical data review on phenotypic heterogeneity and treatment efficacy.
Main Results:
- LRBA/DEF6 facilitates CTLA-4 recycling, crucial for immune tolerance.
- Phenotypic heterogeneity includes infections (CVID, IPEX, ALPS-like), pulmonary/neurological issues, and malignancies.
- Abatacept and sirolimus show efficacy; HSCT is curative; multiomics may personalize therapy.
Conclusions:
- Tailored immunomodulation with abatacept and sirolimus enhances disease control and quality of life.
- Early diagnosis, multidisciplinary care, and timely HSCT are vital for optimal outcomes.
- Gene therapy and AI-driven pathways offer future personalized treatment possibilities.
Purpose Of Review:
CTLA4-related immune disorders are primary immune dysregulation characterized by susceptibility to infections, autoimmunity, hyperinflammation, and malignancies. As new insights into their molecular mechanisms and therapeutic approaches emerge, we aim to provide a review that guides clinicians in diagnosing and adapting management strategies for LRBA deficiency and CTLA-4 insufficiency.
Recent Findings:
Recent studies highlight the importance of LRBA/DEF6-mediated CTLA-4 recycling to maintain immune tolerance. Novel interactions (e.g., NBEAL2, Arf1-Rab4) and BEACH-domain protein function further elucidate disease pathogenesis. Clinically, phenotypic heterogeneity spans susceptibility to infections with CVID, IPEX, and ALPS-like presentations, with emerging recognition of pulmonary and neurological involvement and malignancies. Abatacept and sirolimus therapies have shown superior efficacy in controlling disease manifestations, while hematopoietic stem cell transplantation (HSCT) remains the only curative option. Integration of multiomics data may personalize future therapies.
Summary:
Tailored immunomodulation using abatacept and sirolimus improves disease control and quality of life in LRBA deficiency and CTLA-4 insufficiency. Early diagnosis, multidisciplinary care, and timely HSCT in high-risk patients are critical for optimal outcomes. Ongoing research into gene therapy and artificial intelligence-driven care pathways offers hope for durable, personalized treatment strategies.
More Related Videos
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Cell-mediated Immune Responses
Cells of the Adaptive Immune Response

